T-Cell Therapy Market Size to Hit USD 20.9 billion by 2035| Exclusive Report by Roots Analysis

Cancer is one of the leading causes of mortality across the world. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be one of the most active areas, in terms of drug development, there is still a significant unmet need in this domain. In fact, conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Specifically, chemotherapy and radiation therapy are also associated with several side effects. In addition, their non-specific nature can have severe and detrimental effects on a patient's quality of life.

To request quote of this report, please visit: https://www.rootsanalysis.com/reports/t-cell-therapies-market/request-quote.html

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to selectively eliminate tumor cells with minimal side effects. Immunotherapies essentially make use of the body's own immune system, or its components, to fight cancer. It is a relatively new concept, currently having achieved pharmacological success with targeted antibody-based therapeutics, including monoclonal and conjugated antibodies. However, over the years, different classes of immunotherapies have emerged for the management and treatment of cancer; these include therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors and certain whole cell-based therapies (adoptive cell therapies).

T-Cell Market: Current Market Landscape
During our research, we identified over 1200 CAR-T therapies that have either been approved or are in clinical / preclinical stages of development. The market landscape is fragmented, featuring the presence of both start-ups and well-established companies, indicating the growing interest of stakeholders in this field.. Notably, CAR-T therapies market is dominated by small and mid-sized companies, which is indicative of the fact that this domain is currently evolving and offers opportunities for innovation and growth to the players emerging in this domain.

Further, we identified over 210 TCR-based and 90 TIL-based therapies that have either been approved or are in clinical / preclinical stages of development for the treatment of oncological and non-oncological disorders. Notably, majority of the TCR-based therapies are being developed for the treatment of lung cancer; whereas most of the TIL-based therapies are being developed against melanoma.

To request a sample copy / brochure of this report, please visit: https://www.rootsanalysis.com/reports/t-cell-therapies-market/request-sample.html

Several Industry And Non-Industry Players Are Conducting Clinical Trials To Evaluate Different Cell Therapies Intended For Treatment Of Various Target Indications, Across Different Geographies

Over the past few years, there has been a notable increase in the number of CAR-T therapies for the treatment of various target indications, with major focus on oncological disorders. Notably, pharmaceutical companies invest a significant portion of research and development in conducting extensive clinical studies for these therapies. Besides the abovementioned trials, close to 15% of clinical studies have been completed in the CAT-T domain, followed by 14% of clinical trials that are active, but not yet recruiting patients. Further, majority of the trials in this domain have been evaluated for hematological cancer.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/t-cell-therapies-market/261.html

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.